H S Pathology Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 15-11-2024
- Paid Up Capital ₹ 0.20 M
as on 15-11-2024
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.00 M
as on 15-11-2024
- Revenue -31.37%
(FY 2023)
- Profit -728.75%
(FY 2023)
- Ebitda -496.21%
(FY 2023)
- Net Worth 7.83%
(FY 2023)
- Total Assets 40.18%
(FY 2023)
About H S Pathology
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.20 M.
The company has closed loans amounting to ₹1.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Deepak Abhayakumar and Abhaya Mayur serve as directors at the Company.
- CIN/LLPIN
U74990TN2010PTC169600
- Company No.
202832
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 2010
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at H S Pathology?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhaya Mayur  | Director | 05-Sep-2022 | Current |
| Deepak Abhayakumar | Director | 20-Aug-2024 | Current |
Financial Performance and Corporate Structure Insights of H S Pathology.
H S Pathology Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 31.37% decrease. The company also saw a substantial fall in profitability, with a 728.75% decrease in profit. The company's net worth moved up by a moderate rise of 7.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of H S Pathology?
In 2023, H S Pathology had a promoter holding of 28.32% and a public holding of 71.68%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Venkata Narayana Active Ingredients Private LimitedActive 19 years 3 monthsDeepak Abhayakumar is a mutual person
Novocura Tech Health Services Private LimitedActive 7 years 10 monthsAbhaya Mayur is a mutual person
Cellutions Biostorage Private LimitedActive 3 years 8 monthsDeepak Abhayakumar and Abhaya Mayur are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 14 Oct 2013 | ₹1.00 M | Satisfied |
How Many Employees Work at H S Pathology?
H S Pathology has a workforce of 79 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of H S Pathology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped H S Pathology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
